Arcutis Biotherapeutics has climbed 30% in a month and nearly 6% in a week, yet nearly 13% of the float remains short — a setup where the stock's momentum and its skeptics are heading in opposite directions ahead of a Q2 print on August 4.
The borrow market tells a notably relaxed story given the short interest level. Availability is loose — over 1,000% relative to shares already borrowed — meaning there is ample capacity for new shorts to build positions without any squeeze pressure. Cost to borrow has more than halved over the past month to just 0.31%, near the lowest readings in the 30-day window. So while short interest at 12.9% of the float is genuinely elevated, the shorts are sitting comfortably and facing no mechanical pressure to cover. The ORTEX short score has also eased, pulling back from 65.3 at the end of June to 61.6 now, suggesting the composite pressure on shorts is actually declining even as the stock has rallied. Options positioning corroborates the lean-bullish tone: the put/call ratio is running at 0.097, well below its 20-day average of 0.135 and near its 52-week low of 0.093. That's about one put per ten calls — historically the most one-sided call-heavy reading of the past year.
The Street is broadly constructive but the most recent analyst data is from early May, which limits its freshness. At that point, the consensus held multiple Buy-rated targets clustered in the $34–$36 range against a current price of $27.67, implying roughly 25% upside from current levels. Goldman Sachs sits at Neutral with a $29 target — close to where the stock trades today — providing the clearest bearish anchor on the Street. Bulls point to Zoryve's commercial expansion into primary care and pediatrics, and to extraordinary forward EPS momentum: the 12-month forward EPS estimate ranks in the 97th percentile for year-on-year growth. The earnings surprise factor score of 87 adds to the bull case, reflecting a consistent track record of beating estimates. Bears flag the competitive pressure from Vtama, payor access risks, and third-party manufacturing dependency — all structural concerns that haven't gone away as the stock has run.
The earnings history adds a note of caution to the rally. The most recent print, on June 5, produced a modest 1.9% single-day decline but recovered to gain 11% over five sessions. The one before that, on May 6, was harder: an 11.8% drop on day one with a further 7.4% loss over the following week. Two prints is a thin sample, but the pattern is uneven — the stock has punished misses sharply. Against a 30% monthly run into August 4, the bar for the Q2 release will be meaningfully higher than the last time around.
State Street added roughly 808,000 shares through June 30, and BlackRock added 262,000 in the same period — incremental institutional accumulation that aligns with the stock's rise. Marshall Wace, typically an active hedge fund, added nearly 2 million shares as of the March 31 filing, a more aggressive commitment. Among correlated small-cap biotech peers, PTGX gained 15.8% on the week and AKBA surged 22.5%, suggesting the broader small-cap biotech tape has been strong — providing a sector tailwind rather than an ARQT-specific signal.
The tension to watch into August 4 is whether the commercial Zoryve execution story holds up under Q2 revenue scrutiny, and whether the 12.9% short base — well-funded, cheaply borrowed, and not under squeeze pressure — begins to move before or after the print.
See the live data behind this article on ORTEX.
Open ARQT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
